Immunotherapy for malignant melanoma with a tumor cell vaccine.

Published

Journal Article (Review)

Specific active immunotherapy for melanoma has been administered to several thousand patients since 1972, using an irradiated whole-cell preparation. A humoral response to vaccination can be demonstrated in a large percentage of patients. This response increases while immunizations are continued and decreases after cessation of therapy. The vaccinations are well tolerated; however, the therapeutic impact of this whole-cell vaccine awaits a randomized trial for definitive evaluation.

Full Text

Duke Authors

Cited Authors

  • Slingluff, CL; Seigler, HF

Published Date

  • January 1, 1992

Published In

Volume / Issue

  • 28 / 1

Start / End Page

  • 104 - 107

PubMed ID

  • 1642395

Pubmed Central ID

  • 1642395

International Standard Serial Number (ISSN)

  • 0148-7043

Digital Object Identifier (DOI)

  • 10.1097/00000637-199201000-00026

Language

  • eng

Conference Location

  • United States